@article{Kennedy_N-2021_45549,
title = {Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD},
author = {Kennedy, N. and Lin, S. and Goodhand, J. and Chanchlani, N. and Hamilton, B. and Bewshea, C. and Nice, R. and Chee, D. and Cummings, J. and Fraser, A. and Irving, P. and Kamperidis, N. and Kok, K. and Lamb, Christopher A. and MacDonald, J. and Mehta, S. and Pollok, R. and Raine, T. and Smith, P. and Verma, A. and Jochum, S. and McDonald, T. and Sebastian, S. and Lees, C. and Powell, N. and Ahmad, T.},
month = {apr},
year = {2021},
abstract = {OBJECTIVE: Delayed second dose SARS-CoV-2 vaccination trades maximal effectiveness for a lower level of immunity across more of the population. We investigated whether patients with inflammatory bowel disease treated with infliximab have attenuated serological responses to a single dose of a SARS-CoV-2 vaccine.},
pages = {1884-1893},
volume = {70},
issue = {10},
journal = {Gut},
publisher = {BMJ Publishing Group},
url = {http://dx.doi.org/10.1136/gutjnl-2021-324789},
}
